Spyre Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Plans
During the fiscal quarter ended June 30, 2025, no director or Section 16 officer adopted orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K), except as described below.
On June 20, 2025, Cameron Turtle, our Chief Executive Officer, terminated a trading plan dated April 12, 2024 intended to satisfy Rule 10b5-1(c) to sell up to 300,000 shares of our common stock over a period ending November 19, 2026, subject to certain conditions, andadopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 360,000 shares of our common stock over a period ending August 4, 2027, subject to certain conditions.
On June 20, 2025, Sheldon Sloan, our Chief Medical Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 102,958 shares of our common stock over a period ending September 3, 2026, subject to certain conditions, all of which shares are to be acquired upon the exercise of employee stock options.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.